Maravai LifeSciences Holdings, Inc. (MRVI) Bundle
A Brief History of Maravai LifeSciences Holdings, Inc.
Maravai LifeSciences Holdings, Inc. (MRVI), incorporated in August 2020, has established itself as a key player in the life sciences sector, particularly in nucleic acid production and biologics safety testing. The company operates through its principal asset, a controlling equity interest in Topco LLC, enabling it to consolidate financial operations and report a non-controlling interest related to the portion of Topco LLC not owned by Maravai.
Financial Performance Overview
As of June 30, 2024, Maravai reported total revenue of $137.6 million for the first half of the year, down from $147.9 million in the same period of 2023, reflecting a decrease of 7.0%.
| Period | Revenue (in thousands) | Net Loss (in thousands) | Net Loss per Share |
|---|---|---|---|
| 6 Months Ended June 30, 2024 | $137,579 | $37,172 | $(0.15) |
| 6 Months Ended June 30, 2023 | $147,939 | $13,291 | $(0.05) |
Segment Performance
Revenue from the Nucleic Acid Production segment decreased from $114.7 million in the first half of 2023 to $104.5 million in 2024, a decline of 8.9%. Conversely, the Biologics Safety Testing segment showed minor resilience, with revenue slightly decreasing from $33.2 million to $33.1 million.
| Segment | Revenue (in thousands) | Change (%) |
|---|---|---|
| Nucleic Acid Production | $104,499 | -8.9% |
| Biologics Safety Testing | $33,080 | -0.4% |
Operating Expenses
Total operating expenses for the first half of 2024 amounted to $165.9 million, up from $157.0 million in 2023, marking a increase of 5.7%.
| Expense Category | 6 Months 2024 (in thousands) | 6 Months 2023 (in thousands) | Change (%) |
|---|---|---|---|
| Cost of Revenue | $76,606 | $76,949 | -0.4% |
| Selling, General & Administrative | $81,441 | $74,048 | +10.0% |
| Research & Development | $10,316 | $8,339 | +23.7% |
Net Loss Analysis
The net loss for the first half of 2024 was $37.2 million, compared to $13.3 million in the same period of 2023, reflecting a substantial increase of 179.7%.
Liquidity and Capital Resources
As of June 30, 2024, Maravai had cash and cash equivalents of $573.2 million. The company generated positive cash flow from operations amounting to $9.0 million for the first half of the year. Capital expenditures for the same period totaled $10.4 million.
| Financial Metric | Value (in thousands) |
|---|---|
| Cash and Cash Equivalents | $573,200 |
| Positive Cash Flow from Operations | $9,000 |
| Capital Expenditures | $10,400 |
Debt Obligations
As of June 30, 2024, Maravai’s long-term debt stood at $530.4 million, with future principal maturities outlined as follows:
| Year | Debt Maturity (in thousands) |
|---|---|
| 2024 (remaining six months) | $2,720 |
| 2025 | $5,440 |
| 2026 | $5,440 |
| 2027 | $516,800 |
A Who Owns Maravai LifeSciences Holdings, Inc. (MRVI)
Ownership Structure
As of June 30, 2024, Maravai LifeSciences Holdings, Inc. (MRVI) holds approximately 56.1% of the outstanding LLC Units of Topco LLC. The remaining 43.9% of the outstanding LLC Units are held by MLSH 1. This ownership structure is crucial as it determines the reporting of non-controlling interests in the financial statements, reflecting the portion of profit or loss attributable to the non-controlling interests in Topco LLC.
Non-Controlling Interests
The non-controlling interests represent the portion of profit or loss, net assets, and comprehensive income or loss of Maravai's consolidated subsidiaries that is not allocable to the company based on its percentage of ownership. As of June 30, 2024, the non-controlling interests in Topco LLC amounted to approximately $339.5 million.
Shareholder Breakdown
The following table summarizes the shares outstanding for Maravai LifeSciences Holdings, Inc. as of June 30, 2024:
| Share Class | Shares Issued | Amount (in $) | Additional Paid-In Capital (in $) | Retained Earnings (in $) | Total Stockholders’ Equity (in $) |
|---|---|---|---|---|---|
| Class A Common Stock | 141,489 | 1,415 | 168,337 | 266,074 | 436,933 |
| Class B Common Stock | 110,684 | 1,107 | N/A | N/A | N/A |
| Total | 252,173 | 2,522 | 168,337 | 266,074 | 776,414 |
Recent Changes in Ownership
In May 2024, MLSH 1 exchanged 8,409,946 LLC Units of Topco LLC, paired with an equal number of shares of Class B common stock, for an equal number of shares of Class A common stock. Following this exchange, the Class B common stock was subsequently canceled and retired.
Financial Performance Overview
For the six months ended June 30, 2024, Maravai LifeSciences reported a total revenue of $137.6 million, down from $147.9 million in the same period of 2023. The revenue breakdown includes:
| Segment | Revenue (in $) | Percentage of Total Revenue |
|---|---|---|
| Nucleic Acid Production | 104,499 | 76.0% |
| Biologics Safety Testing | 33,080 | 24.0% |
| Total | 137,579 | 100.0% |
The decrease in revenue was primarily attributed to lower demand in research and discovery products and the timing of GMP-related mRNA builds for customers.
Net Loss Reporting
For the six months ended June 30, 2024, Maravai LifeSciences reported a net loss of $37.2 million, compared to a net loss of $13.3 million for the same period in 2023. The net loss attributable to Maravai LifeSciences Holdings, Inc. was $19.7 million.
Stock Performance
As of June 30, 2024, the weighted average number of Class A common shares outstanding was 134,088. The net loss per Class A common share attributable to Maravai LifeSciences was reported at $(0.15), compared to $(0.05) in 2023.
Conclusion of Ownership Dynamics
The ownership dynamics of Maravai LifeSciences Holdings, Inc. reflect a significant portion held by its controlling entity, with MLSH 1 as a major non-controlling interest holder. Recent transactions have further shaped the equity landscape, impacting overall financial performance and share metrics.
Maravai LifeSciences Holdings, Inc. (MRVI) Mission Statement
Overview of Mission Statement
Maravai LifeSciences Holdings, Inc. aims to be a leader in providing critical tools and services to the life sciences industry. Their mission is to enable scientists and researchers to accelerate the development of life-saving therapies and diagnostics. The company focuses on enhancing the quality and efficacy of their products to meet the evolving needs of their customers.
Core Values
- Innovation: Commitment to continuous improvement and advancement in technology.
- Quality: Ensuring the highest standards in products and services.
- Collaboration: Working closely with clients to understand and fulfill their needs.
- Integrity: Upholding ethical standards and transparency in all operations.
Financial Performance Metrics
As of June 30, 2024, Maravai LifeSciences reported a total revenue of $73.4 million for the three months ended, compared to $68.9 million for the same period in 2023, marking a 6.5% increase. The six-month revenue for 2024 stood at $137.6 million, down from $147.9 million in 2023, reflecting a 7.0% decrease.
| Metric | Q2 2024 | Q2 2023 | Change (%) |
|---|---|---|---|
| Total Revenue | $73.4 million | $68.9 million | 6.5% |
| Nucleic Acid Production Revenue | $58.5 million | $53.3 million | 9.8% |
| Biologics Safety Testing Revenue | $14.9 million | $15.6 million | -4.7% |
| Net Loss | $(14.5) million | $(11.9) million | 21.3% |
Investment in Research and Development
Maravai has significantly increased its investment in research and development, spending $5.3 million in Q2 2024 compared to $4.2 million in Q2 2023, which is a 25.9% increase. For the first half of 2024, R&D expenses totaled $10.3 million, up from $8.3 million in the previous year.
Market Focus and Strategic Goals
The company is primarily focused on two segments: Nucleic Acid Production and Biologics Safety Testing. As of June 30, 2024, Nucleic Acid Production accounted for approximately 79.7% of total revenue, while Biologics Safety Testing contributed 20.3%. Maravai aims to expand its customer base internationally while strengthening relationships with existing clients.
| Segment | Revenue (Q2 2024) | Revenue (Q2 2023) | % of Total Revenue (Q2 2024) |
|---|---|---|---|
| Nucleic Acid Production | $58.5 million | $53.3 million | 79.7% |
| Biologics Safety Testing | $14.9 million | $15.6 million | 20.3% |
Financial Summary
Maravai’s financial outlook remains focused on sustainable growth through operational efficiency and strategic investments. As of June 30, 2024, the company holds cash and cash equivalents amounting to $573.2 million, providing a robust buffer for future investments and operational needs.
| Financial Metric | Amount |
|---|---|
| Cash and Cash Equivalents | $573.2 million |
| Retained Earnings | $266.1 million |
| Total Assets | $1.447 billion |
| Total Liabilities | $671.2 million |
| Stockholders' Equity | $776.4 million |
How Maravai LifeSciences Holdings, Inc. (MRVI) Works
Business Model
Maravai LifeSciences Holdings, Inc. operates primarily in the life sciences sector, focusing on providing products and services essential for research, development, and manufacturing in the biotechnology and pharmaceutical industries. The company has two main segments:
- Nucleic Acid Production
- Biologics Safety Testing
Financial Performance
As of June 30, 2024, Maravai reported the following financial results:
| Metric | Q2 2024 | Q2 2023 | Change |
|---|---|---|---|
| Revenue | $73,400,000 | $68,914,000 | +6.5% |
| Operating Expenses | $82,912,000 | $80,528,000 | +3.0% |
| Loss from Operations | ($9,512,000) | ($11,614,000) | -18.1% |
| Net Loss | ($14,492,000) | ($11,943,000) | +21.3% |
| Net Loss Attributable to Maravai | ($7,585,000) | ($6,541,000) | +16.0% |
| Net Loss per Class A Common Share | ($0.05) | ($0.05) | 0% |
Segment Revenue Analysis
Revenue by segment for the six months ended June 30, 2024, is as follows:
| Segment | Revenue (2024) | Revenue (2023) | Change |
|---|---|---|---|
| Nucleic Acid Production | $104,499,000 | $114,716,000 | -8.9% |
| Biologics Safety Testing | $33,080,000 | $33,223,000 | -0.4% |
| Total Revenue | $137,579,000 | $147,939,000 | -7.0% |
Operating Expenses
Operating expenses for the six months ended June 30, 2024, are detailed below:
| Expense Type | Amount (2024) | Amount (2023) | Change |
|---|---|---|---|
| Cost of Revenue | $76,606,000 | $76,949,000 | -0.4% |
| Selling, General and Administrative | $81,441,000 | $74,048,000 | +10.0% |
| Research and Development | $10,316,000 | $8,339,000 | +23.7% |
| Total Operating Expenses | $165,952,000 | $157,020,000 | +5.7% |
Cash Flow and Liquidity
As of June 30, 2024, Maravai had cash and cash equivalents amounting to $573.2 million, indicating significant liquidity to support its operations and future growth initiatives.
Net cash provided by operating activities for the six months ended June 30, 2024, was $8.967 million.
Debt Obligations
As of June 30, 2024, Maravai's long-term debt consisted of:
| Debt Type | Amount |
|---|---|
| Term Loan | $530,400,000 |
| Less: Unamortized Debt Issuance Costs | ($7,877,000) |
| Total Long-Term Debt | $522,523,000 |
Market Presence
Revenue derived from North America accounted for 44.0% and 47.7% of total revenue for the three and six months ended June 30, 2024, respectively, compared to 49.8% and 50.6% in the same periods of 2023.
Research and Development
Maravai's commitment to R&D is evident with expenditures of $10.316 million for the six months ended June 30, 2024, compared to $8.339 million in the same period of 2023, reflecting a focus on innovation and product development.
Tax Receivable Agreement (TRA)
Maravai has a Tax Receivable Agreement that outlines payments to certain equity holders based on tax attributes arising from exchanges of LLC units. The estimated future payments under the TRA are projected at approximately $7.1 million.
Non-Controlling Interests
As of June 30, 2024, non-controlling interests represented about 43.9% of the outstanding LLC Units of Topco LLC.
How Maravai LifeSciences Holdings, Inc. (MRVI) Makes Money
Revenue Streams
Maravai LifeSciences operates primarily through two segments: Nucleic Acid Production and Biologics Safety Testing. As of the second quarter of 2024, the consolidated revenue was reported as follows:
| Segment | Q2 2024 Revenue (in thousands) | Q2 2023 Revenue (in thousands) | Change (%) |
|---|---|---|---|
| Nucleic Acid Production | $58,483 | $53,265 | 9.8% |
| Biologics Safety Testing | $14,917 | $15,649 | (4.7%) |
| Total Revenue | $73,400 | $68,914 | 6.5% |
For the six months ended June 30, 2024, total revenue was $137,579, a decrease of 7.0% from $147,939 in 2023. The Nucleic Acid Production segment generated $104,499, down 8.9% from $114,716, while Biologics Safety Testing was marginally down from $33,223 to $33,080.
Nucleic Acid Production
This segment is the largest revenue generator for Maravai, accounting for approximately 79.7% of total revenue in Q2 2024. It includes the manufacture and sale of complex nucleic acid products such as:
- CleanCap®
- GMP mRNA
- Specialized oligonucleotides
- Enzymes
Revenue recognition occurs when control is transferred to the customer, typically upon shipment. The increase in revenue in this segment is attributed to higher demand for GMP CleanCap analogs and the Glen Research product portfolio.
Biologics Safety Testing
This segment focuses on products and services that support biologic drug manufacturing, including:
- Host cell protein detection
- Viral clearance prediction kits
- Custom antibody development
In Q2 2024, revenue from Biologics Safety Testing decreased by 4.7% due to lower demand trends, particularly in China.
Cost Structure
The operating expenses for Maravai LifeSciences for Q2 2024 were as follows:
| Expense Category | Q2 2024 (in thousands) | Q2 2023 (in thousands) | Change (%) |
|---|---|---|---|
| Cost of Revenue | $38,271 | $43,273 | (11.6%) |
| Selling, General and Administrative | $40,556 | $35,377 | 14.6% |
| Research and Development | $5,284 | $4,194 | 26.0% |
| Total Operating Expenses | $82,912 | $80,528 | 3.0% |
The cost of revenue saw a decrease primarily due to lower direct labor and overhead expenses, while selling, general, and administrative expenses increased significantly due to stock-based compensation and depreciation expenses.
Net Loss and Financial Performance
Maravai reported a net loss of $14,492 for Q2 2024, compared to a net loss of $11,943 in Q2 2023. The loss attributable to Maravai LifeSciences was $7,585 for Q2 2024, translating to a net loss per Class A share of $(0.05).
Adjusted EBITDA
Adjusted EBITDA for the segments was reported as follows:
| Segment | Q2 2024 Adjusted EBITDA (in thousands) | Q2 2023 Adjusted EBITDA (in thousands) |
|---|---|---|
| Nucleic Acid Production | $21,301 | $14,192 |
| Biologics Safety Testing | $9,445 | $10,315 |
| Total Adjusted EBITDA | $30,746 | $24,507 |
Adjusted EBITDA increased due to improved performance in the Nucleic Acid Production segment, despite a slight decline in Biologics Safety Testing.
Capital Expenditures and Investments
For the six months ended June 30, 2024, capital expenditures totaled $10.4 million, primarily for property and equipment purchases.
Debt Obligations
As of June 30, 2024, Maravai's long-term debt consisted of:
| Debt Type | Amount (in thousands) |
|---|---|
| Term Loan | $530,400 |
| Less: Current Portion | $(5,440) |
| Total Long-term Debt | $522,523 |
The effective interest rate on the Term Loan was 8.33% per annum.
Maravai LifeSciences Holdings, Inc. (MRVI) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support